Table 3 Clinical characteristics for patients with or without omentectomy
Clinical patient characteristics | No omentectomy n =121 (21.6%) | Omentectomy n =438 (78.4%) | P -value |
|---|---|---|---|
Age at first diagnosis | |||
Median, years | 53 | 48 | 0.192a |
Range | (16–92) | (14–86) | |
FIGO stage | <0.001b | ||
IA/B | 81 (67.0%) | 198 (45.2%) | |
IC | 23 (19.0%) | 111 (25.3%) | |
IIA-C | 14 (11.6%) | 51 (11.7%) | |
IIIA-C | 3 (2.5%) | 78 (17.8%) | |
Surgical approach in primary and re-staging surgery | <0.001b | ||
Laparoscopy | 32 (26.4%) | 43 (9.8%) | |
Laparotomy | 89 (73.6%) | 395 (90.2%) | |
Surgical procedures in primary and re-staging surgery c | |||
Bilateral salpingo-oophorectomy | 81 (66.9%) | 369 (84.2%) | <0.001b |
Unilateral salpingo-oophorectomy | 29 (24.0%) | 106 (24.2%) | 0.958b |
Cystectomy | 27 (22.3%) | 76 (17.4%) | 0.221b |
Hysterectomy | 62 (51.2%) | 336 (76.7%) | <0.001b |
Peritoneal biopsies | 30 (24.8%) | 344 (78.5%) | <0.001b |
Cytology | 56 (46.3%) | 326 (74.4%) | <0.001b |
Appendectomy | 14 (11.6%) | 151 (34.5%) | <0.001b |
Pelvic LND/LN biopsies | 15 (12.4%) | 103 (23.5%) | 0.005b |
Para-aortic LND/LN biopsies | 7 (5.8%) | 70 (16.0%) | 0.002b |
Peritoneal implants in primary or re-staging surgery | <0.001b | ||
None | 107 (88.4%) | 321 (73.3%) | |
Non-invasive | 12 (9.9%) | 98 (22.4%) | |
Invasive | 2 (1.7%) | 19 (4.3%) | |
Surgical cytoreduction | 0.530b | ||
Complete | 109 (90.1%) | 408 (93.2%) | |
Incomplete | 2 (1.7%) | 6 (1.4%) | |
Unknown | 10 (8.3%) | 24 (5.5%) | |
Staging quality after primary and re-staging surgery | <0.001b | ||
Adequate | 0 (0.0%) | 278 (63.5%) | |
Inadequate | 121 (100.0%) | 160 (36.5%) | |
Fertility-sparing surgery | <0.001b | ||
Yes | 40 (33.1%) | 70 (16.0%) | |
No | 81 (66.9%) | 368 (84.0%) | |
Up-staging after re-staging surgery | 0.026b | ||
Yes | 2 (1.7%) | 27 (6.2%) | |
No | 119 (98.3%) | 411 (93.8%) | |
Recurrent disease | 0.029b | ||
Yes | 18 (14.9%) | 35 (8.0%) | |
Borderline tumour | 14/18 (77.8%) | 26/35 (74.3%) | |
High grade carcinoma | 1/18 (5.6%) | 3/35 (8.6%) | |
Low grade carcinoma | 2/18 (11.1%) | 6/35 (17.1%) | |
Unknown | 1/18 (5.6%) | 0/35 (0.0%) | |
No | 103 (85.1%) | 403 (92.0%) | |
Site of recurrent disease c | |||
Ovarian tissue | 8/18 (44.4%) | 18/35 (51.4%) | |
Ipsilateral | 4/18 (22.2%) | 5/35 (14.3%) | |
Contralateral | 4/18 (22.2%) | 16/35 (45.7%) | |
Peritoneum | 5/18 (27.8%) | 23/35 (65.7%) | |
Omentum | 1/18 (5.6%) | 0/35 (0.0%) | |
Other | 0/18 (0.0%) | 2/35 (5.8%) | |
Unknown | 5/18 (27.8%) | 5/35 (14.3%) | |
5-year progression-free survival | 79.9% | 89.3% | 0.004d |
5-year disease-specific survival | 98.8% | 99.7% | 0.893d |
